The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy

Ana Morales; Ray E Hershberger

doi:10.1016/j.cjca.2015.06.034

The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy

Can J Cardiol. 2015 Nov;31(11):1309-12. doi: 10.1016/j.cjca.2015.06.034. Epub 2015 Jul 9.

Authors

Ana Morales¹, Ray E Hershberger²

Affiliations

¹ Division of Human Genetics, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA; Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.
² Division of Human Genetics, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA; Cardiovascular Division, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA; Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA. Electronic address: ray.hershberger@osumc.edu.

Abstract

The genetic evaluation of dilated cardiomyopathy (DCM) has been challenging, owing in large part to marked genetic heterogeneity. However, lower costs from next-generation sequencing have enabled gene discovery and the expansion of genetic testing panels. These advances have improved molecular diagnostics and predictive testing in DCM. We provide a rationale and recommendation for clinical genetic testing in all DCM cases.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Cardiomyopathy, Dilated / diagnosis*
Cardiomyopathy, Dilated / genetics*
Genetic Predisposition to Disease*
Genetic Testing / methods*
Humans
Time Factors

Abstract

Publication types

MeSH terms

Grants and funding